Literature DB >> 24587820

Clostridium difficile infection: management strategies for a difficult disease.

Sahil Khanna1, Darrell S Pardi2.   

Abstract

Clostridium difficile was first described as a cause of diarrhea in 1978 and in the last three decades has reached an epidemic state with increasing incidence and severity in both healthcare and community settings. There also has been a rise in severe outcomes from C. difficile infection (CDI). There have been tremendous advancements in the field of CDI with the identification of newer risk factors, recognition of CDI in populations previously thought not at risk and development of better diagnostic modalities. Several treatment options are available for CDI apart from metronidazole and vancomycin, and include new drugs such as fidaxomicin and other options such as fecal microbiota transplantation. This review discusses the epidemiology, risk factors and outcomes from CDI, and focuses primarily on existing and evolving treatment modalities.

Entities:  

Keywords:  Clostridium difficile infection; management; recurrent infection; risk factors; severe infection

Year:  2014        PMID: 24587820      PMCID: PMC3903088          DOI: 10.1177/1756283X13508519

Source DB:  PubMed          Journal:  Therap Adv Gastroenterol        ISSN: 1756-283X            Impact factor:   4.409


  109 in total

1.  Proton pump inhibitors and risk for recurrent Clostridium difficile infection.

Authors:  Amy Linsky; Kalpana Gupta; Elizabeth V Lawler; Jennifer R Fonda; John A Hermos
Journal:  Arch Intern Med       Date:  2010-05-10

Review 2.  Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.

Authors:  Jason W Lancaster; S James Matthews
Journal:  Clin Ther       Date:  2012-01       Impact factor: 3.393

3.  Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection.

Authors:  Mary Y Hu; Kianoosh Katchar; Lorraine Kyne; Seema Maroo; Sanjeev Tummala; Valley Dreisbach; Hua Xu; Daniel A Leffler; Ciarán P Kelly
Journal:  Gastroenterology       Date:  2008-12-13       Impact factor: 22.682

4.  Fidaxomicin failures in recurrent Clostridium difficile infection: a problem of timing.

Authors:  Robert Orenstein
Journal:  Clin Infect Dis       Date:  2012-05-18       Impact factor: 9.079

5.  Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.

Authors:  Jacques Pépin; Nathalie Saheb; Marie-Andrée Coulombe; Marie-Eve Alary; Marie-Pier Corriveau; Simon Authier; Michel Leblanc; Geneviève Rivard; Mathieu Bettez; Valérie Primeau; Martin Nguyen; Claude-Emilie Jacob; Luc Lanthier
Journal:  Clin Infect Dis       Date:  2005-09-20       Impact factor: 9.079

Review 6.  Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections.

Authors:  Christina M Surawicz; Lawrence J Brandt; David G Binion; Ashwin N Ananthakrishnan; Scott R Curry; Peter H Gilligan; Lynne V McFarland; Mark Mellow; Brian S Zuckerbraun
Journal:  Am J Gastroenterol       Date:  2013-02-26       Impact factor: 10.864

7.  Fecal microbiota transplantation--an old therapy comes of age.

Authors:  Ciarán P Kelly
Journal:  N Engl J Med       Date:  2013-01-16       Impact factor: 91.245

8.  Community-associated Clostridium difficile infection: how real is it?

Authors:  Fernanda C Lessa
Journal:  Anaerobe       Date:  2013-02-08       Impact factor: 3.331

9.  Increase in Clostridium difficile-related hospitalizations among infants in the United States, 2000-2005.

Authors:  Marya D Zilberberg; Andrew F Shorr; Marin H Kollef
Journal:  Pediatr Infect Dis J       Date:  2008-12       Impact factor: 2.129

10.  Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial.

Authors:  Marlene Wullt; Marie-Louise Johansson Hagslätt; Inga Odenholt
Journal:  Scand J Infect Dis       Date:  2003
View more
  20 in total

1.  Epidemiology, outcomes, and predictors of mortality in hospitalized adults with Clostridium difficile infection.

Authors:  Sahil Khanna; Arjun Gupta; Larry M Baddour; Darrell S Pardi
Journal:  Intern Emerg Med       Date:  2015-12-22       Impact factor: 3.397

2.  Ipilimumab-associated colitis or refractory Clostridium difficile infection?

Authors:  Arjun Gupta; Sahil Khanna
Journal:  BMJ Case Rep       Date:  2015-07-07

Review 3.  Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis.

Authors:  Raseen Tariq; Siddharth Singh; Arjun Gupta; Darrell S Pardi; Sahil Khanna
Journal:  JAMA Intern Med       Date:  2017-06-01       Impact factor: 21.873

4.  New-Onset Microscopic Colitis in an Ulcerative Colitis Patient After Fecal Microbiota Transplantation.

Authors:  Raseen Tariq; Thomas Smyrk; Darrell S Pardi; William J Tremaine; Sahil Khanna
Journal:  Am J Gastroenterol       Date:  2016-05       Impact factor: 10.864

5.  Gut microbiome predictors of treatment response and recurrence in primary Clostridium difficile infection.

Authors:  Sahil Khanna; Emmanuel Montassier; Bradley Schmidt; Robin Patel; Daniel Knights; Darrell S Pardi; Purna Kashyap
Journal:  Aliment Pharmacol Ther       Date:  2016-08-02       Impact factor: 8.171

6.  Predictors and outcomes of readmission for Clostridium difficile in a national sample of medicare beneficiaries.

Authors:  Courtney E Collins; M Didem Ayturk; Fred A Anderson; Heena P Santry
Journal:  J Gastrointest Surg       Date:  2014-11-19       Impact factor: 3.452

Review 7.  Clostridium difficile infection: Updates in management.

Authors:  Raseen Tariq; Sahil Khanna
Journal:  Indian J Gastroenterol       Date:  2016-12-20

Review 8.  Host response to Clostridium difficile infection: Diagnostics and detection.

Authors:  Elena A Usacheva; Jian-P Jin; Lance R Peterson
Journal:  J Glob Antimicrob Resist       Date:  2016-09-20       Impact factor: 4.035

Review 9.  Novel approaches to treating Clostridium difficile-associated colitis.

Authors:  David Padua; Charalabos Pothoulakis
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-12-07       Impact factor: 3.869

10.  SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI.

Authors:  Abdul Sattar; Pia Thommes; Lloyd Payne; Peter Warn; Richard J Vickers
Journal:  J Antimicrob Chemother       Date:  2015-02-03       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.